accelerating and de-risking drug development and clinical translation. They generate a novel pipeline for our BioPharma partners and license out our IP, expanding their patient reach. Evol’s first biological discovery has generated multiple novel drug combinations to treat late-stage, RAS-driven cancers including metastatic melanoma, pancreatic, colorectal, breast, and lung. They expect to have their first combination in proof-of-principle clinical trials in the first half of 2019. Their goal is to make the deadliest cancers survivable.